Compare ResMed Inc. (RMD) vs State Street Real Estate Select Sector SPDR ETF (XLRE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
ResMed Inc. vs State Street Real Estate Select Sector SPDR ETF — how do they compare? ResMed Inc. trades at $194.34 (market cap $28.81B), while State Street Real Estate Select Sector SPDR ETF trades at $45.34. The key difference: ResMed Inc. pays a 1.21% dividend while State Street Real Estate Select Sector SPDR ETF pays none, and State Street Real Estate Select Sector SPDR ETF is trading nearer its 52-week high, ResMed Inc. nearer its low. Which is the better fit depends on your goals.
| RMD | XLRE | |
|---|---|---|
Market Cap | $28.81B | — |
Sector | Health | Sector/Thematic |
52-Week High | $293.73 | $45.46 |
52-Week Low | $182.82 | $40.01 |
Enterprise Value | $27.99B | — |
Dividend Yield | 1.21% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ResMed (RMD) trades at $195.8, down 1.6% on the day, with a bearish technical signal but strong fundamentals. Recent quarterly earnings have consistently beaten estimates, with Q1 2026 EPS of $2.86 exceeding the $2.80 forecast. The company sold its MatrixCare business for $490 million in July 2026 to sharpen focus on connected care, signaling strategic refinement. Revenue growth remains robust, climbing to $5.15 billion in 2025, with net income margins expanding to 27.44%.
The outlook is supported by solid earnings momentum and a consensus price target of $245.88, implying 25.6% upside. Risks include competitive pressures in medical equipment and reliance on sleep apnea market growth. Analyst sentiment is mixed with 40% buy ratings, but institutional selling by Baader Bank in Q1 2026 warrants monitoring.
XLRE, the Real Estate Select Sector SPDR ETF, trades at $45.23 with a slight 0.42% decline. Technical indicators show a bullish trend with strong moving average support, though RSI suggests potential overbought conditions. The ETF has gained 11% year-to-date, benefiting from REIT sector recovery despite interest rate volatility. Recent news highlights XLRE's low 0.08% expense ratio advantage and steady dividend yield around 3.4%.
Outlook remains cautiously optimistic as REIT fundamentals improve with stable NOI growth and potential M&A activity. Key risks include interest rate sensitivity and inflation pressures. Wall Street sentiment is positive with the sector showing resilience amid broader market volatility, though investors should monitor Fed policy shifts that could impact real estate valuations.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About ResMed Inc.
ResMed is one of the largest respiratory care device companies globally, primarily developing and supplying flow generators, masks and accessories for the treatment of sleep apnea. Increasing diagnosis of sleep apnea combined with ageing populations and increasing prevalence of obesity is resulting in a structurally growing market. The company earns roughly two thirds of its revenue in the Americas and the balance across other regions dominated by Europe, Japan and Australia. Recent developments and acquisitions have focused on digital health as ResMed is aiming to differentiate itself through the provision of clinical data for use by the patient, medical care advisor and payer in the out-of-hospital setting.
Read more on RMD →About State Street Real Estate Select Sector SPDR ETF
XLRE tracks the Real Estate Select Sector Index, providing exposure to S&P 500 real estate companies. It focuses on equity REITs across residential, industrial, and healthcare sub-sectors, with top holdings like Welltower, Prologis, and American Tower.
Read more on XLRE →
